EUVIMEDEUVIMED entdecken
Open Access

Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis

Robert W Yeh, Richard Shlofmitz, Jeffrey Moses, William Bachinsky, Suhail Dohad, Steven Rudick, Robert Stoler, Brian K Jefferson, William Nicholson, John Altman, Cinthia Bateman, Amar Krishnaswamy und 14 weitere

JAMA · 26.03.2024 · 331 (12) · 1015

DOI: 10.1001/jama.2024.1361 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 26.03.2024. Verfasst von Robert W Yeh und 25 weiteren Autor:innen. Beteiligte Einrichtung: Beth Israel Deaconess Medical Center, Boston, Massachusetts. Hauptthemen laut MEDLINE: Coronary Restenosis, Myocardial Infarction. Die Arbeit wurde bisher 169-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Drug-coated balloons offer a potentially beneficial treatment strategy for the management of coronary in-stent restenosis. However, none have been previously evaluated or approved for use in coronary circulation in the United States.

Objective

To evaluate whether a paclitaxel-coated balloon is superior to an uncoated balloon in patients with in-stent restenosis undergoing percutaneous coronary intervention. Design, Setting, and Participants AGENT IDE, a multicenter randomized clinical trial, enrolled 600 patients with in-stent restenosis (lesion length <26 mm and reference vessel diameter >2.0 mm to ≤4.0 mm) at 40 centers across the United States between May 2021 and August 2022. One-year clinical follow-up was completed on October 2, 2023.

Interventions

Participants were randomized in a 2:1 allocation to undergo treatment with a paclitaxel-coated (n = 406) or an uncoated (n = 194) balloon. Main Outcomes and Measures The primary end point of 1-year target lesion failure—defined as the composite of ischemia-driven target lesion revascularization, target vessel–related myocardial infarction, or cardiac death—was tested for superiority.

Results

Among 600 randomized patients (mean age, 68 years; 157 females [26.2%]; 42 Black [7%], 35 Hispanic [6%] individuals), 574 (95.7%) completed 1-year follow-up. The primary end point at 1 year occurred in 17.9% in the paclitaxel-coated balloon group vs 28.6% in the uncoated balloon group, meeting the criteria for superiority (hazard ratio [HR], 0.59 [95% CI, 0.42-0.84]; 2-sided P = .003). Target lesion revascularization (13.0% vs 24.7%; HR, 0.50 [95% CI, 0.34-0.74]; P = .001) and target vessel–related myocardial infarction (5.8% vs 11.1%; HR, 0.51 [95% CI, 0.28-0.92]; P = .02) occurred less frequently among patients treated with paclitaxel-coated balloon. The rate of cardiac death was 2.9% vs 1.6% (HR, 1.75 [95% CI, 0.49-6.28]; P = .38) in the coated vs uncoated balloon groups, respectively. Conclusions and Relevance Among patients undergoing coronary angioplasty for in-stent restenosis, a paclitaxel-coated balloon was superior to an uncoated balloon with respect to the composite end point of target lesion failure. Paclitaxel-coated balloons are an effective treatment option for patients with coronary in-stent restenosis. Trial Registration ClinicalTrials.gov Identifier: NCT04647253

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary RestenosisMyocardial InfarctionFemaleHumansAgedPaclitaxelStentsTreatment OutcomeDeath

Substanzen

Paclitaxel

Autor:innen und Institutionen

  • Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • St Francis Hospital, Roslyn, New York.
  • Columbia University Irving Medical Center/NewYork-Presbyterian Hospital and the Cardiovascular Research Foundation, New York.
  • University of Pittsburgh Medical Center, Harrisburg, Pennsylvania.
  • Cedars Sinai Medical Center, Los Angeles, California.
  • Lindner Center for Research and Education at Christ Hospital, Cincinnati, Ohio.

Zitieren

APA

Yeh, R. W., Shlofmitz, R., Moses, J., Bachinsky, W., Dohad, S., Rudick, S., Stoler, R., Jefferson, B. K., Nicholson, W., Altman, J., Bateman, C., Krishnaswamy, A., Grantham, J. A., Zidar, F. J., Marso, S. P., Tremmel, J. A., Grines, C., Ahmed, M. I., Latib, A., …, & AGENT IDE Investigators (2024). Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis. JAMA, 331(12), 1015. https://doi.org/10.1001/jama.2024.1361

Vancouver

Yeh RW, Shlofmitz R, Moses J, Bachinsky W, Dohad S, Rudick S, et al. Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis. JAMA. 2024;331(12):1015. doi:10.1001/jama.2024.1361

BibTeX
@article{Yeh2024,
  author = {Yeh, Robert W and Shlofmitz, Richard and Moses, Jeffrey and Bachinsky, William and Dohad, Suhail and Rudick, Steven and Stoler, Robert and Jefferson, Brian K and Nicholson, William and Altman, John and Bateman, Cinthia and Krishnaswamy, Amar and Grantham, J Aaron and Zidar, Frank J and Marso, Steven P and Tremmel, Jennifer A and Grines, Cindy and Ahmed, Mustafa I and Latib, Azeem and Tehrani, Behnam and Abbott, J Dawn and Batchelor, Wayne and Underwood, Paul and Allocco, Dominic J and Kirtane, Ajay J and AGENT IDE Investigators, AGENT IDE Investigators},
  title = {Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis},
  journal = {JAMA},
  year = {2024},
  volume = {331},
  number = {12},
  pages = {1015},
  doi = {10.1001/jama.2024.1361}
}
Kostenlos starten →